Menu
Back to Journals » Patient Preference and Adherence » Volume 4
Clinical utility and patient adherence with ebastine for allergic rhinitis
Authors Ciprandi G
Published 14 October 2010 Volume 2010:4 Pages 389—395
DOI https://doi.org/10.2147/PPA.S8186
Review by Single anonymous peer review
Peer reviewer comments 2
Giorgio Ciprandi
Department of Internal Medicine, San Martino Hospital, Genoa, Italy
Abstract: Allergic rhinitis (AR) is a high prevalence disease, affecting 10%–20% of the general population. AR is sustained by an IgE-mediated reaction, and by a complex inflammatory network of cells, mediators, and cytokines, becoming chronic when exposure to allergen persists. A Th2-biased immune response is the basis for the allergic inflammation. Histamine plays a relevant role in symptom occurrence. Therefore, antihistamine use represents a cornerstone in AR management. Ebastine, a novel antihistamine, is effective overall in controlling symptoms, and its safety profile is good. Recently, a new formulation has been developed, ie, a fast-dissolving tablet. Several studies have demonstrated its favorable characteristics. In conclusion, ebastine is an effective and well tolerated antihistamine that may be prescribed for the treatment of AR. The fast-dissolving tablet formulation provides a new option which may be particularly convenient for the patient.
Keywords: allergic rhinitis, histamine, antihistamines, ebastine, tablets
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.